ClinicalTrials.gg
RecruitingNCT05527470Updated May 3, 2023

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

A Phase 3 interventional study of Gemcitabine,Cisplatin and Intensity-modulated radiation therapy (IMRT) in Nasopharyngeal Carcinoma, sponsored by Wei Jiang. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Wei Jiang · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing gemcitabine in Nasopharyngeal Carcinoma — 11 open to participants now, 15 under way, 7 of them phase 3. Gemcitabine · Nasopharyngeal Carcinoma.

Planned enrollment
5th of 26
440 · median 152
Started
2022
with 1 other
Phase 3
10 of 26
3 open now
Primary completion
2025-11
later than 4 of 14 live
Registered
17th of 26
by date

Among the 26 studies testing gemcitabine in Nasopharyngeal Carcinoma, this one is the 5th largest by planned enrollment, is one of 2 that started in 2022, is one of 10 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 17th registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

11 of the 26 studies testing gemcitabine in Nasopharyngeal Carcinoma are open now, in 9 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing gemcitabine in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

In the era of comprehensive therapy, many studies have investigated the value of induction chemotherapy (IC) in the treatment of nasopharyngeal carcinoma (NPC). Concurrent cisplatin and radiotherapy is the foundation of concurrent chemoradiotherapy strategies, and the addition of cisplatin-based induction chemotherapy to concurrent chemoradiotherapy (CCRT) is considered to prolong survival by reducing distant metastasis in patients with high-risk disease. However, the severity of acute toxicities was significantly increased, which can compromise quality of life and lead to interruptions in CCRT. Fortunately, Locoregional control has substantially improved as the intensity-modulated radiation therapy (IMRT) technique has been widely used in the last decades, IMRT improved the treatment outcomes of patients with NPC, especially the local control rate. Currently, in the era of IMRT, whether patients with NPC benefit from IC plus radiotherapy alone and reduce toxicities compared with IC combined with CCRT. Therefore, the investigators propose this randomized phase III prospective study to assess the efficacy and contribution of IC plus radiotherapy alone in locoregionally advanced NPC during IMRT era.

Read the detailed description

Patients with stage III-IVA (AJCC 8th, included T1-2N2-3 and/or T3-4N0-3 M0) locoregionally-advanced nasopharyngeal carcinoma will be randomized in a 1:1 ratio to experimental arm and active comparator arm. Patients in experimental arm will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration. Patients in active comparator arm will receive induction chemotherapy with gemcitabine (1g/m2, d1 \& 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 3 cycles during IMRT.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • Nasopharyngeal Carcinoma
  • Chemoradiotherapy
  • Radiotherapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with newly confirmed non-keratinizing (according to WHO histologically type);
  2. Tumor staged as III-IVb (according to the 8th AJCC edition);
  3. No pregnant female;
  4. Age between 18-65;
  5. Normal complete blood count level ( >10 g/dL, white blood cells ≥4000/μL, ≥100 000/μL);
  6. Normal hepatic functions (serum total ≤1.6 mg/dL, serum transminase \< 2.5 times higher than upper limit);
  7. Normal renal function (serum creatinine ≤1.5 mg/dL, ≥60 mL/min);
  8. (ECOG) performance status of 0 or 1;
  9. Without radiotherapy or chemotherapy;
  10. Patients must give signed .

Exclusion criteria

Exclusion Criteria:

  1. Disease progression in the process of the treatment;
  2. The presence of uncontrolled life-threatening illness;
  3. History of previous radiotherapy or chemotherapy;
  4. Pregnancy or lactation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • Active comparator
    Induction CT+IMRT Combined Concurrent CT

    Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy

    Drug: Gemcitabine,Cisplatin · Radiation: Intensity-modulated radiation therapy (IMRT) · Drug: Cisplatin

  • Experimental
    Induction CT+IMRT alone

    Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone

    Drug: Gemcitabine,Cisplatin · Radiation: Intensity-modulated radiation therapy (IMRT)

Interventions

  • DrugGemcitabine,Cisplatin

    Drug pages: GemcitabineStudies of GemcitabineGemcitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8, 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.

    Also known as: Induction chemotherapy regimen

  • RadiationIntensity-modulated radiation therapy (IMRT)

    IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were \> 66 Gy to the primary tumor and \> 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.

  • Concurrent chemotherapy: Patients received 100mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.

    Also known as: Concurrent chemotherapy regimen

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival is from randomization to first disease progression \[local recurrence and/or distant metastasis\] or death from any cause

    Time frame: 3 years

Secondary outcomes

  1. Overall Survival

    Overall survival is from randomization to death of any cause or last follow-up

    Time frame: 3 years

  2. Locoregional Failure-free Survival

    Locoregional failure-free survival is from randomization to locoregional progression

    Time frame: 3 years

  3. Distant Failure-free Survival

    Distant failure-free survival is from randomization to first distant metastasis

    Time frame: 3 years

  4. Objective response rate

    Objective response rate is the percentage of patients achieving complete response (CR) and partial response (PR) according to RECIST 1.1 criteria.

    Time frame: 3 years

  5. Number of Participants with Adverse Events

    Incidence of acute and late toxicity

    Time frame: 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2025, 36 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2022
First posted
Sep 2, 2022
StartActual
Nov 11, 2022
Primary completionEst.
Nov 11, 2025
CompletionEst.
Nov 11, 2027
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05527470
Lead sponsor
Wei Jiang
Collaborators
Wuzhou Red Cross Hospital, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Lingshan people's Hospital, Laibin People's Hospital, Nationalities Hospital of Guangxi Zhuang Autonomous Region
Responsible party
Wei Jiang (Principal Investigator, Guilin Medical University, China) — Sponsor-investigator
First posted
Sep 2, 2022
Start date
Nov 11, 2022
Primary completion
Nov 11, 2025 (estimated)
Completion
Nov 11, 2027 (estimated)
Last update
May 3, 2023

Study contacts

Wei Jiang, PhD
Contact
weijiang@glmc.edu.cn
+86-2882906

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion